Correspondence 0001493152-23-001391 from Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc.
Date: Jan. 13, 2023 · CIK: 0001716947 · Accession: 0001493152-23-001391
AI Filing Summary & Sentiment
File numbers found in text: 333-269157
Show Raw Text
CORRESP
1
filename1.htm
Ensysce
Biosciences, Inc.
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California 92037
January
13, 2023
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Attention:
Tyler Howes, Esq.
Re:
Ensysce
Biosciences, Inc.
Registration
Statement on Form S-3
SEC
File No. 333-269157
Ladies
and Gentlemen:
Pursuant
to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc.
(the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3
(File No. 333-269157) (the “Registration Statement”) be accelerated to 4:00 PM, Eastern Time, on Tuesday, January
17, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders
LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our
counsel by calling Gregory Rubis, Esq. at (609) 951-4105.
Please
direct any questions or comments concerning this request to Mr. Rubis of Troutman Pepper Hamilton Sanders LLP.
ENSYSCE
BIOSCIENCES, INC.
By:
/s/
Lynn Kirkpatrick
Name:
Lynn
Kirkpatrick
Title:
CEO
Cc:
Eric
D. Kline, Troutman Pepper Hamilton Sanders LLP
Gregory
Rubis, Troutman Pepper Hamilton Sanders LLP